Following cardiological assessment and the decision to initiate ICI therapy, pre- and early-treatment serum hsTnT concentrations should be measured and closely monitored especially during the initial treatment cycles where the risk of irM is greatest, particularly in patients with additional risk factors for irM, including the male sex, diabetes, a history of heart disease, and those undergoing combined anti-PD1 and anti-CTLA4 immunotherapy. This evidence concerns the gene CTLA4 and diabetes mellitus.